Subtyping of breast cancer using reverse phase protein arrays.
Reverse phase protein arrays (RPPAs) present a robust and sensitive high capacity platform for targeted proteomics that relies on highly specific antibodies to obtain a quantitative readout regarding phosphorylation state and abundance of proteins of interest. This review summarizes the current state of RPPA-based proteomic profiling of breast cancer in the context of existing preanalytical strategies and sample preparation protocols. RPPA-based subtypes identified so far are compared to those obtained by other approaches such as immunohistochemistry, genomics and transcriptomics. Special attention is given to discussing the potential of RPPA for biomarker discovery and biomarker validation.
Division of Molecular Genome Analysis, German Cancer Research Center (DKFZ) Im Neuenheimer Feld 580 69120 Heidelberg, Germany.
Johanna
J
Sonntag
Kerstin
K
Schlüter
Stephan
S
Bernhardt
Ulrike
U
Korf
D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism* / Q000473:pathology; D005260:Female; D020869:Gene Expression Profiling; D006801:Humans; D011379:Prognosis; D040081:Protein Array Analysis; D020543:Proteome / Q000378:metabolism*; D040901:Proteomics; D018719:Erb-b2 Receptor Tyrosine Kinases / Q000378:metabolism; D011960:Receptors, Estrogen / Q000378:metabolism; D064726:Triple Negative Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism / Q000473:pathology
D014408:Biomarkers, Tumor; D020543:Proteome; D018719:Erb-b2 Receptor Tyrosine Kinases; D011960:Receptors, Estrogen; C508053:ERBB2 protein, human
HER2; RPPA; breast cancer; hormone receptor; molecular subtyping; reverse phase protein array; signaling pathways